Emerging evidence suggests voice dysfunction is the earliest sign of motor impairment in
Parkinson's disease (PD). The complexity and fine motor control involved in vocalization …

Abstract Development of neuroprotective therapeutics for Parkinson's disease (PD) is facing
a lack of translation from pre-clinical to clinical trials. One strategy for improvement is to …

Previous studies demonstrate that intrastriatal injections of fibrillar alpha-synuclein (α-syn)
into mice induce Parkinson's disease (PD)-like Lewy body (LB) pathology formed by …

One key limitation in developing effective treatments for neurodegenerative diseases is the
lack of models accurately mimicking the complex physiopathology of the human disease …

Parkinson's disease (PD) is a progressive neurodegenerative disease that leads to a wide
range of motor and nonmotor deficits. Specifically, voice and swallow deficits manifest early …

Objective Patients with idiopathic rapid eye movement sleep behaviour disorder (RBD) are
at substantial risk for developing Parkinson's disease (PD) or related neurodegenerative …

Mice communicate through audible vocalizations, which are within the human hearing
range, and ultrasonic vocalizations (USVs), which are above the upper limit of human …

Mutations in the transcription factor Forkhead box p1 (FOXP1) are causative for
neurodevelopmental disorders such as autism. However, the function of FOXP1 within the …

Aberrant accumulation and self-assembly of α-synuclein are tightly linked to several
neurodegenerative diseases called synucleinopathies, including idiopathic Parkinson's …

Abstract Parkinson's disease (PD), a neurodegenerative disorder, is traditionally classified
as a movement disorder. Patients typically suffer from many motor dysfunctions. Presently …